Iovance Biotherapeutics 的转移性黑色素瘤治疗药物 Amtagvi 获得 FDA 加速批准,导致股价飙升 41%。 Iovance Biotherapeutics' metastatic melanoma treatment, Amtagvi, received accelerated FDA approval, causing a 41% stock surge.
在美国 FDA 加速批准其转移性黑色素瘤治疗药物 Amtagvi 后,Iovance Biotherapeutics 股价飙升 41%。 Iovance Biotherapeutics shares soared 41% after the US FDA granted accelerated approval for its metastatic melanoma treatment, Amtagvi. 该公司计划利用 2.11 亿美元承销股票发行的收益来支持 Amtagvi 的商业推出并为正在进行的临床项目提供资金。 The company plans to use the proceeds from a $211m underwritten stock offering to support the commercial launch of Amtagvi and fund ongoing clinical programs. 这对于 Iovance 来说是一个重要的里程碑,因为它从一家临床阶段的生物技术公司转变为一家拥有可销售产品的公司。 This marks a significant milestone for Iovance as it transitions from a clinical-stage biotech to a company with a marketable product.